{"title":"Feasibility of assessing male osteoporosis using MRI IDEAL-IQ sequence of proximal femur in prostate cancer patients.","authors":"Daisuke Watanabe, Takahiro Kimura, Kazuki Yanagida, Takahiro Yoshida, Norikazu Kawae, Takahiro Nakamura, Hajime Kajihara, Akio Mizushima","doi":"10.1080/13685538.2022.2112663","DOIUrl":null,"url":null,"abstract":"<p><p>Osteoporosis is often accompanied by bone loss with fat accumulation of the red marrow. A novel technique for quantification of iron and fat content by MRI IDEAL-IQ can visualize hematopoietic areas and fatty deposits in bone marrow; however, the relationship between these indices and total hip bone mineral density (BMD) remains unclear. In this study, the proximal femur of 104 men who underwent pelvic MRI and bone densitometry prior to treatment for non-metastatic prostate cancer was retrospectively examined to investigate the R2* value to quantify iron and proton density fat fraction (PDFF) to assess bone marrow fat content. R2* was significantly positively correlated with BMD (<i>r</i> = 0.6017, <i>p</i> < 0.0001), and PDFF was not correlated with BMD (<i>r</i> = -0.1302, <i>p</i> = 0.0512). Patients with BMD T-score ≤ -2.5 had significantly lower R2* than patients with BMD T-score > -2.5; however, there was no significant difference in PDFF. In the ROC analysis, which examined the predictive ability of R2* with BMD T-score ≤ -2.5 as an outcome, the cut-off value of R2* was 50.7 <i>s</i><sup>-1</sup> (AUC 0.817). These results show R2* correlated with BMD. R2* may be a non-invasive surrogate marker for diagnosing male osteoporosis.</p>","PeriodicalId":55542,"journal":{"name":"Aging Male","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aging Male","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13685538.2022.2112663","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 2
Abstract
Osteoporosis is often accompanied by bone loss with fat accumulation of the red marrow. A novel technique for quantification of iron and fat content by MRI IDEAL-IQ can visualize hematopoietic areas and fatty deposits in bone marrow; however, the relationship between these indices and total hip bone mineral density (BMD) remains unclear. In this study, the proximal femur of 104 men who underwent pelvic MRI and bone densitometry prior to treatment for non-metastatic prostate cancer was retrospectively examined to investigate the R2* value to quantify iron and proton density fat fraction (PDFF) to assess bone marrow fat content. R2* was significantly positively correlated with BMD (r = 0.6017, p < 0.0001), and PDFF was not correlated with BMD (r = -0.1302, p = 0.0512). Patients with BMD T-score ≤ -2.5 had significantly lower R2* than patients with BMD T-score > -2.5; however, there was no significant difference in PDFF. In the ROC analysis, which examined the predictive ability of R2* with BMD T-score ≤ -2.5 as an outcome, the cut-off value of R2* was 50.7 s-1 (AUC 0.817). These results show R2* correlated with BMD. R2* may be a non-invasive surrogate marker for diagnosing male osteoporosis.
骨质疏松症常伴有骨质流失和红骨髓脂肪堆积。MRI IDEAL-IQ定量铁和脂肪含量的新技术可以可视化骨髓造血区和脂肪沉积;然而,这些指标与髋部总骨密度(BMD)之间的关系尚不清楚。在这项研究中,104名非转移性前列腺癌治疗前接受骨盆MRI和骨密度测量的男性股骨近端回顾性检查,研究R2*值量化铁和质子密度脂肪分数(PDFF)以评估骨髓脂肪含量。R2*与BMD呈显著正相关(r = 0.6017, p r = -0.1302, p = 0.0512)。BMD t -评分≤-2.5的患者R2*显著低于BMD t -评分> -2.5的患者;但PDFF无显著性差异。在以BMD t评分≤-2.5为结果检验R2*预测能力的ROC分析中,R2*的截断值为50.7 s-1 (AUC 0.817)。这些结果表明R2*与BMD相关。R2*可能是诊断男性骨质疏松症的非侵入性替代标志物。
期刊介绍:
The Aging Male , the official journal of the International Society for the Study of the Aging Male, is a multidisciplinary publication covering all aspects of male health throughout the aging process. The Journal is a well-recognized and respected resource for anyone interested in keeping up to date with developments in this field. It is published quarterly in one volume per year.
The Journal publishes original peer-reviewed research papers as well as review papers and other appropriate educational material that provide researchers with an integrated perspective on this new, emerging specialty. Areas of interest include, but are not limited to:
Diagnosis and treatment of late-onset hypogonadism
Metabolic syndrome and related conditions
Treatment of erectile dysfunction and related disorders
Prostate cancer and benign prostate hyperplasia.